HRT for gender transition: separating real effects from TikTok mythology

What's this video probably claiming?

Based on the caption and hashtag combination, @grayandbleu is sharing a personal account of hormone replacement therapy as part of a gender transition journey. The creator identifies under nonbinary and MTF (male-to-female) labels, suggesting the HRT involved is feminizing hormone therapy, likely estradiol with or without anti-androgens, not testosterone. The TRT category tag on this video is likely a platform miscategorization. What we're actually dealing with here is feminizing HRT: the physical, emotional, and identity-related changes that come with suppressing endogenous testosterone and introducing exogenous estrogen. Videos in this genre typically touch on timeline of physical changes, emotional shifts, the ambiguity of non-binary identity within binary medical frameworks, and the difficulty of accessing care. The "long and confusing" framing in the caption suggests this creator is also addressing how gender identity and medical transition don't always map neatly onto each other, which is clinically real and worth taking seriously.

What does the science actually show?

Feminizing HRT in people assigned male at birth (AMAB) typically involves estradiol (oral, patch, gel, or injectable) dosed to achieve serum levels of 100-200 pg/mL, often alongside androgen blockers like spironolactone (100-200 mg/day) or bicalutamide. A 2021 systematic review by Angus et al. in Clinical Endocrinology confirmed that feminizing HRT produces meaningful but gradual changes: breast development over 2-3 years, reduced body hair density, redistribution of subcutaneous fat, and decreased muscle mass. Testosterone suppression typically occurs within weeks of starting anti-androgens, but full feminization takes years, not months. Emotional effects are real but understudied. A 2020 study by Nguyen et al. in JAMA Surgery found significant reductions in depression and anxiety symptoms in transgender patients who received gender-affirming interventions, with psychological benefit appearing early in treatment. Non-binary patients specifically are underrepresented in the literature, and their outcomes with partial or modified hormone regimens remain poorly characterized.

Where does the social media noise diverge from clinical reality?

TikTok HRT content frequently overpromises timelines. Creators often show dramatic before-and-after comparisons within 3-6 months that don't represent average outcomes. The Angus 2021 review found breast development, for instance, rarely reaches a final stage before 24 months, and significant individual variation exists based on genetics, baseline hormone levels, and adherence. There's also a persistent myth circulating that higher estradiol doses accelerate feminization. They don't, meaningfully, and higher doses increase thromboembolic risk. A 2019 study by Getahun et al. in Annals of Epidemiology found transgender women on feminizing HRT had elevated venous thromboembolism risk compared to cisgender controls, particularly with oral estrogen formulations. Transdermal routes carry lower clotting risk, something most TikTok HRT content ignores entirely. The identity complexity this creator hints at, being non-binary while using feminizing HRT, is real and clinically underserved, but social media tends to flatten it into binary transition narratives.

What should you actually know?

If you're AMAB and considering feminizing HRT, a few things are worth knowing that often get lost in personal experience content. First, non-binary people can and do use feminizing HRT at modified doses to achieve partial feminization, but the clinical evidence base for these individualized regimens is thin. The Endocrine Society 2017 guidelines (Hembree et al., Journal of Clinical Endocrinology and Metabolism) were written largely around binary transition goals and don't offer clear protocols for non-binary patients. Second, informed consent models have expanded access but don't eliminate the need for baseline labs, including CBC, metabolic panel, and sex hormone levels. Third, spironolactone, while commonly used, carries real side effects including hyperkalemia, dizziness, and polyuria that social media glosses over. Bicalutamide is increasingly preferred in some clinics for its cleaner side effect profile. The emotional complexity this creator describes, uncertainty about labels and identity, is not a contraindication to care. It's a normal part of the process that good clinicians should be equipped to support.